Differential Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Sensitivity to Activated Protein C Among Postmenopausal Women: A Randomized Trial

• Published in: Arteriosclerosis, thrombosis, and vascular biology Vol. 23; no. 9; pp. 1671 - 1676
• Main Authors: Oger, Emmanuel, Alhenc-Gelas, Martine, Lacut, Karine, Blouch, Marie-Thérèse, Roudaut, Nathalie, Kerlan, Véronique, Collet, Michel, Abgrall, Jean-François, Aiach, Martine, Scarabin, Pierre-Yves, Mottier, Dominique
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Heart Association, Inc 01.09.2003; Hagerstown, MD Lippincott; American Heart Association
• Subjects: Administration, Cutaneous; Administration, Oral; Biological and medical sciences; Estrogens; Estrogens - administration & dosage; Estrogens - therapeutic use; Female; Hormones. Endocrine system; Human health and pathology; Humans; Life Sciences; Medical sciences; Pharmacology. Drug treatments; Postmenopause; Postmenopause - physiology; Progesterone; Progesterone - administration & dosage; Progesterone - therapeutic use; Protein C; Protein C - metabolism; Human; Replacement therapy; Serine endopeptidases; Enzyme; blood coagulation; Menopause; randomized trial; Oral administration; Pharmacology; APC resistance; Biological activity; Percutaneous route; Factor V; Peptidases; Estroprogestagen; hormone replacement therapy; Hydrolases; Female; Coagulation factor; Comparative study; Protein C (activated)

OBJECTIVE—Activated protein C (APC) resistance not related to the factor V Leiden mutation is a risk factor for venous thrombosis. Oral estrogen replacement therapy (ERT) has been reported to induce APC resistance. Little is known about the effect of transdermal estrogen. METHODS AND RESULTS—We enro...